TCL Archive Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study November 26, 2010
TCL Archive NCI to Press FDA For Quicker Drug Approval, Relaxation Of Survival Impact Requirement June 26, 1987
TCL Archive NCI to Expand Quality of Care Research, Lead HHS Panel On Cancer Care Policy. October 1, 1999
TCL Archive An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists. May 13, 2005
